SOTIO Reports 59% Disease Control in Solid Tumors
Interim Phase 1 data for SOT201 in advanced solid tumor patients were presented at the SITC 41st Annual Meeting in Phoenix, AZ.
Updated on Nov. 6, 2026 in Biotech
SOTIO Biotech presented interim safety and efficacy results from its VICTORIA-01 Phase 1 study of SOT201, a PD-1 targeting IL-15 immunocytokine, at the SITC 41st Annual Meeting. The interim data showed a 59% disease control rate among 22 patients with advanced solid tumors.
Why it matters
Patients in the study had received a median of three prior treatment lines, and two achieved confirmed partial responses after prior checkpoint inhibitor therapy. The results offer early clinical signals for an immunotherapy approach in tumor types that have proven difficult to treat.
The interim analysis enrolled 22 patients with advanced solid tumors, with a recommended dose of 80 µg/kg preceded by a 20 µg/kg priming dose. Most treatment-related adverse events were Grade 1 or 2, though the study remains early and its long-term durability is not yet established.
The players
SOTIO Biotech
A clinical-stage biopharmaceutical company owned by PPF Group that is developing SOT201 for solid tumors.
SITC
The Society for Immunotherapy of Cancer, which hosts an annual meeting for immuno-oncology researchers and clinicians.
The details
SOT201 combines IL-15 superagonist activity with anti-PD-1 targeting to stimulate tumor-specific T cells. Most treatment-related adverse events were Grade 1 or 2, and the findings supported the recommended dose and priming regimen presented at the meeting.
Timeline
The SITC 41st Annual Meeting was held November 6-8, 2026, in Phoenix, AZ.
Poster 1180 on the VICTORIA-01 interim results was presented on Saturday, Nov. 7, 2026.
Big Picture
SOT201 builds on the PD-1 checkpoint inhibitor class that reshaped solid tumor treatment, adding IL-15 stimulation to target patients who had progressed on earlier checkpoint therapy. The two partial responses after prior checkpoint inhibitor treatment suggest the combination is being tested where existing options have run out.
For patients with advanced solid tumors who have already received checkpoint inhibitors, these early results point to a possible treatment path still under study. The therapy remains investigational, so access depends on continued clinical trial enrollment and further evaluation in expanded cohorts.
The takeaway
Early Phase 1 data can signal promise for difficult-to-treat tumors, but interim results from small cohorts require larger, longer studies before conclusions about benefit can be drawn. Readers should watch for expanded cohort results to judge whether these signals hold.
Further reading
For broader context on drug development pipelines, explore the latest Biotech coverage.
Source note: This article includes information reported by The Manila times.
